PureTech Health Plc, a London-listed biotechnology group, has appointed Feng Zhang, a pioneer in the development of the CRISPR/Cas9 gene editing tool, to its scientific advisory board to help guide the development of the company’s portfolio of candidate drugs for central nervous system, gastrointestinal and immune disorders. Dr Zhang is a core institute member of the Broad Institute of the Massachusetts Institute of Technology and Harvard University. He is also an investigator at the McGovern Institute for Brain Research at MIT and an associate professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering.
PureTech announced the appointment on 8 July 2016.
Copyright 2016 Evernow Publishing Ltd